In particular, the tumor antigen MSLN is emerging as an attractive target for cancer immunotherapy, considering its high expression on various tumors, including mesothelioma, ovarian, lung, esophageal, pancreatic, gastric, and breast cancers, which facilitates MSLN-specific CAR-T cells to eliminate these cancers [23, 24]. This evidence concerns the gene MSLN and mesothelioma.